Loading
Duke Street Bio makes DSB2455, a tablet drug that blocks PARP1, a DNA repair enzyme some cancers rely on, while sparing a related enzyme linked to blood-count side effects. It is in an early trial for advanced cancers with DNA repair defects, including cancer that has spread to the brain.
Duke Street Bio Ltd, at 2 Duke Street, London, develops small molecules against DNA damage repair deficiencies in cancer and immuno-oncology targets; it emerged from stealth in May 2022 discussing PARP1 and PARP7 inhibitor programmes. Its development candidate DSB2455 is a brain-penetrant PARP1 inhibitor that the company says is highly selective over PARP2, whose inhibition is linked to blood toxicity with first-generation PARP inhibitors. The European Medicines Agency approved a clinical trial in September 2024, the first patient was dosed in a phase 1 trial in December 2024, and in June 2025 the FDA granted Fast Track designation for patients with homologous recombination deficient brain metastases from triple-negative breast cancer. The registry lists breast, ovarian, metastatic castration-resistant prostate and pancreatic cancers and brain metastases with homologous recombination deficiency. Its first registered cancer trial, NCT06458712, was posted on ClinicalTrials.gov in June 2024.
Shares Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies, PARP, Ovarian cancer, Breast cancer (all types).
Shares Synthetic lethality approaches, PARP inhibitors, PARP, Ovarian cancer.
Shares Synthetic lethality approaches, PARP inhibitors, PARP, Ovarian cancer.
Shares Synthetic lethality approaches, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP inhibitors, PARP, Metastatic castration-resistant prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/